Active Phospholipase A2, Group IIA (PLA2G2A) Homo sapiens (Human) Active protein

PLA2; MOM1; PLA2B; PLA2L; PLA2S; PLAS1; sPLA2(platelets,synovial fluid); Non-pancreatic secretory phospholipase A2; Phosphatidylcholine 2-acylhydrolase 2A

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 80%
  • Isoelectric Point9.5
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Phospholipase A2, Group IIA (PLA2G2A) Packages (Simulation)
  • Active Phospholipase A2, Group IIA (PLA2G2A) Packages (Simulation)
  • APD827Hu01.PNG Under development, coming soon!
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Phospholipase A2, Group IIA (PLA2G2A) is a secreted calcium-dependent enzyme that hydrolyzes phospholipids at the sn-2 position to release arachidonic acid and lysophospholipids, key mediators of inflammation. Primarily expressed in inflammatory cells and various tissues, PLA2G2A plays critical roles in host defense, lipid metabolism, and inflammatory diseases like atherosclerosis and arthritis. Its overexpression is associated with chronic inflammatory conditions and cancer progression. PLA2G2A interacts with Phospholipase A2 Group VII (PLA2G7) by coordinating lipid hydrolysis pathways, where PLA2G7's lipoprotein-associated activity modulates PLA2G2A's pro-inflammatory effects in vascular and immune contexts.Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human PLA2G2A and recombinant human PLA2G7. Briefly, PLA2G2A was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to PLA2G7-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PLA2G2A pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human PLA2G2A and recombinant human PLA2G7 was shown in Figure 1, the EC50 for this effect is 0.038 µg/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian populationNCBI: PMC3891130
  • Yogurt drink fortified with menaquinone-7 improves vitamin K status in a healthy populationPubMed: 26495126

Recommend products